Search

Displaying results 481 - 490 of 10000 in total
  1. Target

    Interleukin-13

    go.drugbank.com/bio_entities/BE0002438
    TargetHumans

    Cytokine that plays important roles in allergic inflammation and immune response to parasite infection (PubMed:8096327, PubMed:8097324). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). Stimulates B-cell pro...

    Synonyms: IL-13
  2. Drug

    Chlorhexidine

    go.drugbank.com/drugs/DB00878
    ApprovedInvestigationalVet approvedWithdrawn

    [L11512] It is one of the most common skin and mucous membrane antiseptic agents in use today. … [L11518,L11512,A190453] Chlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s[A190474] and was introduced to the US in the 1970s.

    Mixtures: Ic-gel, Scrub-stat IV 4%Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Oxybuprocaine

    go.drugbank.com/drugs/DB00892
    ApprovedInvestigational

    Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology.

    Products: Benoxinat 1% - Lösung zur Anästhesie in der Oto-Rhino-Laryngologie, Novain 4 mg/ml Augentropfen, Lösung
  4. Target

    Interleukin-23

    go.drugbank.com/bio_entities/BE0008663
    TargetHumans

    Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells (PubMed:17676044) … Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity (PubMed:11114383).

    Synonyms: IL-12B, IL-23-A
  5. Drug

    Bupivacaine

    go.drugbank.com/drugs/DB00297
    ApprovedInvestigational

    Bupivacaine is a widely used local anesthetic agent.

    Mixtures: Bl, Marbeta L KitSynonyms: DL-Bupivacaine, dl-1-Butyl-2',6'-pipecoloxylidide
  6. Drug

    Conestat alfa

    go.drugbank.com/drugs/DB09228
    Approved

    Marketed as the product Ruconest (FDA), this drug is indicated for the treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults. … Additionally, C4 and C2 cleavage occurs resulting in auto-activation of the complement system.

    Categories: Drugs Used in Hereditary AngioedemaProducts: RUCONEST 2100 U IV ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ İÇEREN FLAKON, 1 ADET
  7. Target

    Interleukin-2 receptor subunit beta

    go.drugbank.com/bio_entities/BE0000651
    TargetHumans

    Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15 (...

    Synonyms: IL-2RB, IL-2R subunit beta
  8. Drug

    Bortezomib

    go.drugbank.com/drugs/DB00188
    ApprovedInvestigational

    [A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis … [L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.

    Synonyms: N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideProducts: BORACTIB 3,5 MG IV/SC ENJEKSIYONLUK ÇÖZELTI IÇIN TOZ ,1 ADET, VELCADE 3,5 MG IV/SC ENJEKSİYONLUK ÇÖZELTİ İÇİN TOZ, 1 ADET
  9. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    It is available as immediate- and extended-release formulations.[L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. … Exenatide is a glucagon-like peptide-1 (GLP-1) analog[L42690].

    Categories: Drugs Used in DiabetesProducts: BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MG, BYETTA 10 µG/40 µL SC KULLANIMA HAZIR DOLU ENJEKSİYON KALEMI ICINDE COZELTI, 2.4 ML (60 DOZ)
  10. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    It was originally approved by the U.S. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.

    Products: TRUXİMA 500 MG/50 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, MABTHERA 100 MG/10 ML IV INFUZYON İÇİN KONSANTRE ÇÖZELTİ İÇEREN FLAKON, 2 ADET